Business · 1 sources covering this

Biocon's Pertuzumab gets EMA CHMP recommendation for breast cancer care

Biocon's Pertuzumab has received a positive EMA CHMP recommendation, becoming the first biosimilar to clear the agency's new tailored clinical development approach for HER2-positive breast cancer

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

Business StandardCenter·1h ago
Biocon's Pertuzumab gets EMA CHMP recommendation for breast cancer care
Biocon's Pertuzumab has received a positive EMA CHMP recommendation, becoming the first biosimilar to clear the agency's new tailored clinical development approach for HER2-positive breast cancer
Read at Business Standard →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/d7b4045c9a53321e9ab501ffef09a04e6991a367"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Biocon's Pertuzumab gets EMA CHMP recommendation for breast cancer care"></iframe>

Biocon's Pertuzumab gets EMA CHMP recommendation for breast cancer care

How 1 sources are covering this

Biocon's Pertuzumab gets EMA CHMP recommendation for breast cancer care

More from Business

Advani, Jaishankar, Rekha, Kejriwal: Why so many VIP voters got SIR notices? What triggered them - Rules explained

Want to work in Australia? These jobs now get visa processing priority

Asian Games 2026: Suchika Tariyal clinches maiden MMA bronze for India

When will FIIs return to the Indian stock market? Bernstein answers

Reader

Trust & legal

Across the network